Dr. Glenn Pierce is currently an independent consultant, entrepreneur-in-residence at Third Rock Ventures and serves on the World Federation of Hemophilia (WFH) and WFHUSA Board of Directors and the National Hemophilia Foundation (NHF) (US) Medical and Scientific Advisory Council. Glenn is also a director of Voyager Therapeutics and Global Blood Therapeutics, two publicly held biotechnology companies. Glenn retired from Biogen in 2014 as senior vice president of Hematology, Cell and Gene Therapies. He had overall R&D responsibility for hemophilia and hemoglobinopathies and led the research and clinical development of extended half-life FVIII and FIX Fc fusions as Chief Medical Officer since joining the company in 2009, culminating in multiple regulatory approvals beginning in 2014. Glenn was also responsible for global medical affairs for Biogen’s portfolio 2012-14. At Biogen, Glenn spearheaded the initiation of a 5-year Humanitarian Aid clotting factor distribution program with WFH, and My Life Our Future, a population-wide genomic biobank initiative with NHF and other partners.
Dr. Pierce has 30 years’ experience in biotechnology research and development, from the bench to the bedside in small, large, public and private biotech/biopharma firms, including Biogen, Bayer, Inspiration, Avigen, Selective Genetics, and Amgen in the areas of tissue regeneration and hematology. He is the co-author of more than 150 scientific papers and has been awarded over 15 patents. Dr. Pierce served on the Medical and Scientific Advisory Council, the Board of Directors and was President of the Board of the National Hemophilia Foundation (U.S.) spanning 1983-2005. Glenn also served on the Blood Products Advisory Committee at the US FDA and the Committee on Blood Safety and Availability at the US Department of Health and Human Services. He received an M.D. and a Ph.D. in Immunology, both from Case Western Reserve University in Cleveland, Ohio and did his postgraduate training in pathology and hematology research at Washington University in St. Louis, Missouri.